The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.

Emoto, Chie; Fukuda, Tsuyoshi; Venkatasubramanian, Raja; Vinks, Alexander A

Emoto, Chie; Fukuda, Tsuyoshi; Venkatasubramanian, Raja; Vinks, Alexander A.

Afiliação

Emoto C; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati.
Fukuda T; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati.
Venkatasubramanian R; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati.
Vinks AA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati.

Br J Clin Pharmacol ; 80(6): 1438-46, 2015 Dec.

Article em En | MEDLINE | ID: mdl-26256674

Assuntos

Citocromo P-450 CYP3A/genética; Imunossupressores/farmacocinética; Polimorfismo Genético; Sirolimo/farmacocinética; Humanos; Mucosa Intestinal/metabolismo; Fígado/metabolismo; Modelos Biológicos; Modelos Genéticos; Estudos Retrospectivos

Palavras-chave

CYP3A4; CYP3A5*3 polymorphism; PBPK model; sirolimus

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polimorfismo Genético / Sirolimo / Citocromo P-450 CYP3A / Imunossupressores Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google